MB
AKRO

MPM BioImpact’s Akero Therapeutics AKRO Stock Holding History

MPM BioImpact’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-460,617
Closed -$12.8M – 44
2024
Q4 		$12.8M Buy
460,617
+68,073
+17% +$2.06M 1.82% 24
2024
Q3 		$11.3M Buy
392,544
+6,554
+2% +$171K 1.69% 21
2024
Q2 		$9.06M Buy
385,990
+53,066
+16% +$1.13M 1.41% 26
2024
Q1 		$8.41M Buy
+332,924
New +$8M 1.35% 30

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MPM BioImpact's AKRO Position: Q1 2025 in Review

MPM BioImpact sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 460,617 shares — an estimated $12.8M sold.

MPM BioImpact first reported a position in AKRO in Q1 2024 and held it in 4 quarters. The position peaked at $12.8M in Q4 2024. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

  • MPM BioImpact reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • MPM BioImpact sold 460,617 Akero Therapeutics shares in Q1 2025, an estimated $12.8M.
  • MPM BioImpact first reported a position in Akero Therapeutics in Q1 2024 and held it in 4 quarters.
  • MPM BioImpact's Akero Therapeutics position peaked at $12.8M in Q4 2024.
  • 240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on MPM BioImpact's 13F filing for Q1 2025, filed 15 May 2025.